COMP <GO>
MDLN vs LLY // FORWARD P/E MULTIPLE
Medline Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MDLN 4
— LLY 8
■ METRIC PARITY
LAST: $32.00 (-1.14%) • MKT CAP: $42.07B
forward-pe
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 32.36% | -24.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 36.4x | -16.12 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 2.30% | +0.78 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 40.21% | -32.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 45.51% | -34.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 9.29 | -6.79 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 66.6 | -35.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.51 | +0.60 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $1.29T | -$1.25T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | LLY REV | MDLN GROSS % | LLY GROSS % | MDLN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $65.18B | 26.4% | 83.0% | $1.30B | $16.81B |
| FY 2024 | $25.51B | $45.04B | 27.3% | 81.3% | $1.42B | $8.82B |
| FY 2023 | $23.23B | $34.12B | — | 79.3% | $639.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
LLY // BETA 0.51